The global pharmaceutical industry faces mounting pressure to deliver safer, more effective drug delivery systems while meeting stringent sustainability requirements. Natural biopolymers are offering the way forward, with chitosan at the head of the field as a novel material for pharmaceutical purposes.
With environmental responsibility coming into focus and regulatory bodies leaning more heavily towards biocompatible products, the potential for chitosan to enter the spotlight for innovative pharmaceutical companies seems not only likely but unequivocal.
Pharmaceutical companies need to consider, when choosing a chitosan manufacturer, the manufacturer’s ability to have a full documentation package in place for pharmaceutical regulatory submissions besides the production capacity.
At Fresh On Time Seafood, we recognize those vital needs and have become a reliable partner for pharmaceutical firms that are looking for a consistent supply of premium quality chitosan solutions. Founded by Bintarna Tardy in 2004, Fresh On Time Seafood is a respected international processor and supplier of quality seafood and chitosan products produced from crab shell.
Our sustainable and disruptive solution is applied across multiple industries, from food to healthcare, cosmetics, agriculture, and water treatment. We are dedicated to providing quality, value, and reliability, and keeping the needs of our customers first.
The Chitosan Revolution in the Pharmaceutical Industry
Pharmaceutical firms throughout the world are realizing the unique advantages of chitosan when compared to synthetic polymers. Polymer chitosan was first found in crustacean shells, but compared with the synthetic counterparts, chitosan has features such as high biocompatibility, biodegradability, and many functional properties that are unachievable with synthetic counterparts.
Sustainable sourcing of chitosan We are well aware of the sustainable sourcing of chitosan, with companies such as Fresh On Time Seafood setting a precedent for the sourcing of high-quality shell waste, which can be used to transform into chitosan of a pharmaceutical grade.
The global chitosan market for pharmaceutical applications is experiencing growth, driven by increasing demand for biocompatible, biodegradable excipients and innovative drug delivery systems. Market growth is supported by regulatory trends favoring natural materials and advancing research in chitosan applications.
Chitosan is now being incorporated by healthcare industry leaders into their drug formulation plans to achieve competitive leadership for safety, efficacy, and regulatory approval timelines.
In modern pharmaceutical development, there is a need for materials for protecting APIs, for prolonging the duration of their release, and for directing their delivery to particular locations in the body. For drug protection, extended release, and targeted delivery, it beats out synthetics easily. And it is a 100% biodegradable, ocean-sourced trip.
Evolution of the Pharmaceutical Industry: The Era Before and After the Chitosan Century
Pre-Chitosan Era: Market Issues and Constraints
Prior to the widespread acceptance of chitosan, drug companies faced large-formulation as well as serious manufacturing problems that actually decreased the overall therapeutic effect and augmented cost.
Drawbacks of Conventional Synthetic Polymers:
Synthetic polymers, including polyethylene glycol (PEG), polyvinyl alcohol (PVA), and a multitude of acrylate- based materials, have been widely used as drug delivery vehicles by pharmaceutical companies. While operational, these materials exhibited both significant limitations on innovation and increased risks associated with development.
Issues, with biocompatibility concerns being the most critical. Artificial polymers often elicited inflammation, demanded thorough safety assessments, and raised long-term toxicity problems that delayed their regulatory approval.
The mucoadhesive properties of the synthetic materials were unsuitable and resulted in effective drug delivery. Conventional encapsulation technologies had limited ability to modulate the release of the API, which, in the case of labile APIs, such as proteins, peptides, and nucleic acids, may reduce their bioavailability.
It was especially challenging for oral insulin administration, as severe GI conditions degraded the drugs of interest before they could be absorbed.
Environmental and Legal Restraints
The pharmaceutical industry before chitosan was struggling to cope with environmental regulations and sustainability drives.
The waste produced by such manufacturing processes and disposal of unused medicines comprising of non-decompose excipients lead to eco issues. Environment pollution was primarily caused by synthetic polymer waste.
‘Natural polymers, as the source of antibacterial agents, offer a new way to fight bacterial infection. The advantage over conventional synthetic antibiotics is that natural antimicrobial agents are biocompatible, non-toxic, and inexpensive. Chitosan is one of the natural polymers that represents a very promising source for the development of antimicrobial agents. agents.’ – Milena A., et al (Source: NIH)
Authorities started to shift their focus towards natural and biodegradable ingredients in the approval processes, meaning companies that only had a synthetic option would be at a competitive disadvantage.
The EMA and FDA began asking for supplementary environmental risk assessments of the NCEs with non‐biodegradable excipients in new drug applications.
Manufacturing and Cost Issues:
Conventional pharmaceutical manufacturing involved intricate processing steps in a bid to attain satisfactory biocompatibility and performance of synthetic materials. Development costs were also increased by numerous purification cycles, safety testing, and regulatory documentation, as well as by the extended time-to-market for new drugs.
Quality control was a continuing problem since synthetic polymer batches often had wide variations in molecular characteristics, requiring extensive testing and discarding of material that was not within specification. Such variabilities resulted in inconsistent drug release rates and therapeutic effects.
Post-Chitosan Conversion: Measurable Industry Benefits
Recognizing these limitations of synthetic polymers, the pharmaceutical industry has increasingly turned to natural alternatives like chitosan. The incorporation of chitosan is offering tangible advances in several domains of processing, fundamentally changing how companies approach drug product design and development.
Unlike the complex manufacturing requirements of synthetic polymers, chitosan’s natural properties provide solutions to many of the cost, quality, and regulatory challenges that have long plagued the industry.
Improved Efficacy of Treatment:
Clinical trials have revealed strong enhancement of the efficacy of drugs when chitosan has been considered. Studies have shown that chitosan-based formulations can improve oral bioavailability for certain protein and peptide drugs, with enhancement levels varying depending on the specific drug, formulation, and study conditions. Results from individual studies should be evaluated within their specific contexts.
Even more impressive are the cases of intranasal delivery. Chitosan nasal vaccines elicit an approximately 60% increase in mucosal antibody response following immunization in comparison with conventional adjuvants, offering enhanced immune protection at reduced vaccine dose.
In wound healing, reduced healing times are shown. 26% more wounds are healed, and there are 40% fewer secondary infections. Clinical studies have shown that it heals chronic wounds. These changes result in cost savings for healthcare and higher scores by patients.
Regulatory Approval Speed:
Some pharmaceutical companies report potentially faster regulatory pathways when using chitosan due to its established safety profile, though approval timelines vary significantly based on specific applications and formulations.
Chitosan has GRAS (Generally Recognized as Safe) status with the FDA for food applications. For pharmaceutical uses, chitosan still requires standard safety testing and regulatory approval processes, though its established safety profile in food applications may provide supporting data.
Fresh On Time Seafood, as your trusted chitosan supplier, provides complete regulatory support packages that streamline FDA submissions and reduce compliance risks.
Sustainability and Corporate Responsibility:
Chitosan users are showing substantial gains in the metrics that are crucial to ESG (Environmental, Social, Governance) performance. Typical carbon footprint reductions ranging from 20 to 30% are achieved when chitosan substitutes for more synthetic polymers in key product areas.
Improvements in waste streams are of particular importance. Chitosan being biodegradable eliminates long- term environmental accumulation worries, and since it stems from marine waste, it also fits in line with circular economy approaches.
Some pharmaceutical companies recently promoting their chitosan products as the so-called “ocean-positive”, which adds value in the eco-friendly market.
Is chitosan a pharmaceutical excipient?
Yes, chitosan is widely used as a pharmaceutical excipient due to its natural, biocompatible, and biodegradable properties. It functions as a binder, disintegrant, and coating agent in tablets and capsules. Chitosan also enhances drug absorption and controls release in various drug delivery systems. Its versatility makes it valuable for both conventional and advanced pharmaceutical formulations.
5 Proven Chitosan Benefits
Excellent biocompatibility and safety for patients
The superior biocompatibility makes chitosan unique to other synthetic polymers for pharmaceutical use. Chitosan is also non-toxic, biocompatible, and biodegradable, comparing favorably with other synthetic materials due to its outstanding human tissue compatibility. As a result, it is suitable for internal use, such as for injectable drugs, ophthalmic solutions, and bio-implants.
The material safely breaks down into a benign substance within the body, assuaging fears of long-term toxicity that bother both makers and regulators. Clinical documentation has always proved chitosan does not elicit inflammatory reactions and tolerance immune responses in most of the patients, thus minimizing the risk of the formulation and easing the regulatory approval process.
This means reduced risk for pharma companies, time to market is accelerated, and better patient outcomes, in a day and age where speed is of the essence.
What are the disadvantages of chitosan?
While chitosan has many benefits, it has some limitations in its raw form. It is only soluble in acidic conditions and has poor mechanical strength, water resistance, and thermal stability. These weaknesses can affect its performance in certain pharmaceutical applications. To address this, chitosan is often combined with other natural or synthetic polymers to improve its properties.
Advanced Drug Delivery Innovation
The Mucoadhesive potential of chitosan alters the drug delivery across various routes of administration. The product develops stable gels and nanoparticles that stick on mucosal surfaces for prolonged absorption and enhanced bioavailability of sensitive APIs.
Pharmaceutical use cases that are leading adoption:
Intranasal vaccines: Chitosan prolongs antigen exposure in the nasal cavity, stimulating oral and systemic immunity, and delivery of antigens and adjuvants protects against tumor challenge.
Therapeutics: Cellular uptake and controlled release of cytotoxic agents with MCM -48 preserved by chitosan nanoparticles.
Oral antibiotics: Chitosan encapsulation reduces the gastrointestinal degradation and enhances the intestinal passage in gastric fluid.
Chitosan Oral Insulin Delivery Systems Improved bioavailability by 40% relative to conventional encapsulation, a dramatic advancement in diabetes therapy.
Chemical modification of chitosan allows pH-sensitive and target delivery systems to be synthesized. Intelligent formulations can be designed to release drugs at certain diseased sites under particular physiological environments (inflammation or tumor location), creating optimal therapeutic efficacy while reducing side effects.
Application of Revolutionized Wound Healing and Tissue Engineering
Outside of drug delivery, chitosan is exerting its influence on wound management and regenerative medicine. The antimicrobial activity, along with cell- proliferating ability, renders it an attractive material for advanced wound dressings, skin grafts, and tissue engineering scaffolds.
In wound dressing practice, chitosan is used in the form of efficient hemostatic barriers, in the promotion of healing processes, and in the protection against microbial invasion. The combinatorial modality of the present invention speeds healing and results in better patient outcomes at reduced costs.
Its depiction as a structural analog of glycosaminoglycans (GAGs) in the extracellular matrix is used in the context of tissue engineering applications.
Unparalleled Tailorability for Targeted Therapy
Pharmaceutical are about precision, and chitosan is a provider, whether it’s the molecular properties or personal properties. Molecular weight, DDA, and solubility can be tailored to meet the specific demands of your application, from ophthalmic solution to injectable gel.
The viscosities, bioadhesion forces, and release performance of the several chitosans were different. Compared to low molecular weight chitosan, with a DDA of 90%, high DDA chitosan has increased binding for mucosal surfaces and faster uptake. This ability to alter the vehicle allows for specific formulations to be tailored for individual therapeutic purposes.
One of the world’s leading manufacturers of chitosan, Fresh On Time Seafood now offers pharmaceutical-grade products tailored to meet exact specifications, with tailor-made molecular weights ranging from low to high and high-purity profiles. Such customization allows for optimum performance tailored to individual pharmaceutical applications.
Regulatory Compliance Meets Sustainability
Many pharmaceutical companies now view environmental responsibility to be a crucial criterion when purchasing, and chitosan has a fantastic environmental profile. It speaks to both circular economy principles and tight regulatory requisitions via the fact that it is a biopolymer from marine renewable sources.
It already has GRAS (Generally Recognized as Safe) status with the U.S. FDA for some uses, and investigations for broader therapeutic applications are ongoing. In Europe, chitosan implementation is increasingly being investigated as a biocompatible carrier for IN and oral vaccine formulations in preclinical and clinical trials.
This regulatory recognition brings forward adoption timings and minimizes development risk for drug manufacturers assimilating chitosans into their product portfolios. Chitosan is a “must-have” in any avant-garde pharmaceutical development strategy.
Want to source pharmaceutical-grade chitosan raw materials fast and risk-free? Contact Fresh On Time Seafood today to talk about how our high-quality shell waste, can fulfill your requirements for chitosan at an unprecedented level of quality, consistency, and traceability.
FAQ
How does chitosan improve drug delivery compared to traditional materials?
Chitosan has mucoadhesive properties, meaning it sticks to mucosal surfaces and helps drugs stay longer in the body, enhancing absorption. This leads to better bioavailability, especially for sensitive compounds like peptides or insulin.
Is chitosan safe for use in human medications?
Yes, chitosan is widely recognized for its safety profile. It’s non-toxic, doesn’t trigger immune reactions in most patients, and is already classified as GRAS (Generally Recognized As Safe) by the U.S. FDA for certain uses.
Why are pharmaceutical companies shifting away from synthetic polymers?
Synthetic polymers often raise red flags during regulatory review due to concerns around toxicity, environmental impact, and inconsistent performance. Chitosan offers a cleaner, greener, and more efficient solution, helping companies meet both regulatory and sustainability goals faster.
Article prepared by Arfadia